Werewolf Therapeutics is backing out of its Watertown headquarters, cutting ties with a sizable Talcott Avenue lease as executives work to conserve cash and rethink the drug pipeline. The pullback follows an asset sale and months of restructuring that sharply reduced headcount and left the biotech's long-term game plan looking murky. For nearby lab vendors and the neighborhood, the retreat is another reminder of how quickly small biotechs can slam on the brakes when clinical timelines and financing fall out of sync.
Lease exit by the numbers
As detailed in the company's quarterly report on Form 10-Q, and reported by StreetInsider, Werewolf entered into an Agreement for Termination of Lease and Voluntary Surrender of Premises with ARE-770/784/790 Memorial Drive, LLC covering the building at 200 Talcott Avenue. The filing says the company leased roughly 25,778 square feet there and agreed to pay an aggregate $2.7 million termination fee, which will represent full satisfaction of remaining payments through October 31, 2026. The company added that it will have no further rent obligations to the landlord after the lease termination date.
Sale to Jazz and a big loan paydown
In early May the company disclosed an asset purchase agreement transferring its JZP898 program to Jazz Pharmaceuticals and said it repaid approximately $31.4 million under its K2 HealthVentures term loan. Werewolf reported $46.5 million in cash and cash equivalents as of March 31, 2026 and said it would update its cash runway guidance in the near term. Those moves, along with the Watertown lease exit, have been detailed in the company's May update and in market filings and local reporting, per Nasdaq, MarketScreener and Boston Business Journal.
Restructuring and leadership churn
The company slashed staff in February, approving a reduction in force that cut about 64% of employees and triggered an estimated $4.1 million one-time severance charge, according to a Form 8-K. The restructuring coincided with the resignations of the chief financial officer and chief medical officer; both will remain under short consulting arrangements, the filing says, per StockTitan.
Local ripple effects and strategic options
Werewolf said it is working with Piper Sandler as an exclusive financial advisor and is evaluating a range of strategic alternatives, including potential sales, mergers or licensing deals, to maximize stockholder value. The company framed those steps as necessary to focus limited resources on its INDUKINE and INDUCER platforms while advisers explore next steps, according to Nasdaq.
What to watch next
Investors and neighbors will be watching whether the asset sale, loan paydown and lease termination are enough to extend Werewolf's runway until a more permanent transaction is found. The company said it will provide updated cash runway guidance in future disclosures, and filings show the lease termination is effective October 31, 2026 unless an earlier surrender occurs, as outlined in the company's report and summarized by StreetInsider.
